Spyre Therapeutics, Inc. (SYRE) Stock Price & How to Invest
Last updated November 2026
Short answer
SYRE is Spyre Therapeutics, a clinical-stage biotech developing long-acting antibodies for inflammatory bowel disease and now dermatology, so investing in it means underwriting a pre-revenue pipeline where value rides on Phase 2 trial readouts, not earnings. The stock has been one of 2026's big biotech movers: as of November 20, 2026 it closed near $94, up about 208% year to date and about 301% over one year, though down about 12% over the past three months.
SYRE stock price
As of 2026-11-20, Spyre Therapeutics, Inc. (SYRE) last closed at $93.47, up 285.3% over the past year. Over the past 52 weeks it has traded between $24.26 and $109.00.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Spyre Therapeutics, Inc.'s investor relations page. Walnut is informational, not investment advice.
SYRE key stats
At $93.47 on November 20, 2026, Spyre Therapeutics, Inc. (SYRE) has a market cap of $8.9B.
- Market cap
- $8.9B
- Price to book
- 9.3
- Beta
- 3.23
Market cap, P/E and yield are measured at the $93.47 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Spyre Therapeutics, Inc. (SYRE)?
The last two weeks for Spyre Therapeutics, Inc., as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- SYRE closed at $93.47 on November 20, 2026, down 10.1% over the past five trading days (from $104.00).
Spyre Therapeutics, Inc. filed no current, quarterly or annual report with the SEC in the last two weeks.
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
What does Spyre Therapeutics, Inc. (SYRE) do?
Spyre Therapeutics (Nasdaq: SYRE) is a clinical-stage biotechnology company building extended half-life antibodies and antibody combinations aimed at inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, and more recently the skin disease hidradenitis suppurativa (HS). Its lead programs target the TL1A pathway (SPY002 and SPY072) and complementary mechanisms such as alpha4beta7 (SPY001) and IL-23 (SPY003), engineered for less frequent dosing (potentially quarterly or twice-yearly) than existing biologics like Entyvio. The company has no marketed products and generates no product revenue; its worth is tied to clinical progress and the large addressable IBD market.
As a pre-revenue name, Spyre trades on pipeline expectations, not fundamentals. Positive Part A readouts from the Phase 2 SKYLINE trial in ulcerative colitis, the last of them for SPY003, completed proof-of-concept for all three monotherapies, and Part B (the combinations) is enrolling ahead of schedule with induction data expected in Q3 2027. The SKYWAY basket trial in rheumatic diseases was mixed: SPY072 showed positive results in the rheumatoid arthritis sub-study in August 2026 but missed its primary endpoints in psoriatic arthritis and axial spondyloarthritis, and Spyre does not plan to advance it in rheumatic diseases. The stock is up about 208% year to date and roughly 301% over one year as of November 20, 2026, closing near $94 for a market cap around $8.9 billion, below a 52-week high of about $111. In early October 2026 Spyre sold about 4.1 million shares at $85 in an upsized $350 million public offering, and the shares fell about 14% on the pricing. Including $378 million of net proceeds from that offering and $18 million of October at-the-market sales, pro forma cash was about $1.47 billion. Proceeds are earmarked for gastroenterology and dermatology programs and Phase 3 readiness: the SKYLIGHT Phase 2 study of the SPY772 combination in HS began in September 2026, and a registrational study of the anti-TL1A monotherapy in HS is planned to start in 2027. The flip side is heavy competition in the TL1A field from far larger players and the usual clinical-trial risk, where a single disappointing data point can reset the valuation.
What's driving Spyre Therapeutics, Inc. (SYRE)?
1. TL1A pipeline and the 2027 catalyst cadence
Spyre's core value driver is its TL1A franchise (SPY002 and SPY072) plus adjacent assets. The 2026 slate of Phase 2 proof-of-concept readouts is largely done: positive SKYLINE Part A data in ulcerative colitis completed proof-of-concept for all three monotherapies, while the SKYWAY rheumatology results were positive only in rheumatoid arthritis. The next major IBD catalyst is SKYLINE Part B induction data for three combinations, expected in Q3 2027. This readout calendar means the stock can re-rate quickly, in either direction, on each data drop.
2. Differentiated long-acting dosing
The company engineers antibodies for extended half-life, with SPY001 reported at roughly 4x the half-life of Entyvio and SPY003 near an 85-day half-life. If confirmed in larger trials, less frequent dosing (quarterly or twice-yearly) and combination potential could differentiate Spyre in a crowded IBD field. Convenience and combinability are the commercial thesis if the drugs work.
3. Strong balance sheet funding the plan
Spyre held about $1.07 billion of cash, cash equivalents and marketable securities with no debt at September 30, 2026, and about $1.47 billion pro forma after $378 million of net proceeds from its October offering at $85 per share and $18 million of at-the-market sales. The company guides to a cash runway into the second half of 2029. That funds the current slate of Phase 2 trials and Phase 3 preparation without a near-term financing cliff. A well-capitalized clinical-stage biotech can pursue multiple shots on goal, though the October raise shows that continued dilution is part of the model.
4. Large IBD and immunology market
IBD and immune-mediated inflammatory diseases represent a multi-billion-dollar market currently served by biologics like Skyrizi, Rinvoq, Entyvio, and Tremfya. Success in even one indication could support meaningful commercial value. The size of the prize is what draws so many competitors into the TL1A race.
5. Expansion into dermatology
The October 2026 offering named a new program to take a TL1A antibody into late-stage development for hidradenitis suppurativa, a chronic inflammatory skin disease, and the pipeline now includes an IL-17A/F antibody. The SKYLIGHT Phase 2 study of the SPY772 combination in HS started in September 2026, with topline week-16 results planned for late 2027 or early 2028, and a registrational study of the anti-TL1A monotherapy in HS is planned to start in 2027. Moving beyond IBD widens the potential market for the long-acting platform, but each new indication adds trial cost and its own clinical risk, and the SKYWAY misses show that results in one disease do not carry over automatically.
What are the risks to Spyre Therapeutics, Inc. (SYRE)?
Spyre is pre-revenue and unprofitable, with net losses of about $264 million across the last four reported quarters, including $96.1 million in Q3 2026 as R&D spending roughly doubled to $89.2 million, and analysts expect losses of about $3.04 per share in 2026 and $3.69 in 2027 as trials scale, so the valuation rests entirely on future clinical success. Its programs are mostly early to mid-stage, and Phase 2 results do not guarantee Phase 3 or approval; SPY072's misses in the psoriatic arthritis and axial spondyloarthritis sub-studies of SKYWAY already closed off rheumatic diseases for that antibody. The TL1A space is intensely competitive, with Merck's tulisokibart already reporting registrational ulcerative colitis data and Roche, Sanofi/Teva, and others racing ahead, meaning Spyre may reach market later than established rivals. The stock is highly volatile (beta near 3, a 52-week range of about $23 to $111), and equity raises such as the October 2026 $350 million offering and at-the-market sales dilute holders. Any clinical, regulatory, or safety setback carries outsized downside for a company with no product sales.
What is the Spyre Therapeutics, Inc. (SYRE) forecast?
15 analysts publish price targets on SYRE, averaging $123.87 as of November 2026, or +32.5% against the $93.47 share price on November 20, 2026. The published targets run from $114.00 to $141.00, a narrow spread, and the ratings split 17 buy, 1 hold, 0 sell. Over the last six months there have been 2 raises and 4 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full SYRE forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is SYRE a buy or a sell?
We give no verdict on Spyre Therapeutics, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. TL1A pipeline and the 2027 catalyst cadence. Spyre's core value driver is its TL1A franchise (SPY002 and SPY072) plus adjacent assets. The most optimistic published target, $141.00, assumes this works close to its best case.
The case against. Spyre is pre-revenue and unprofitable, with net losses of about $264 million across the last four reported quarters, including $96.1 million in Q3 2026 as R&D spending roughly doubled to $89.2 million, and analysts expect losses of about $3.04 per share in 2026 and $3.69 in 2027 as trials scale, so the valuation rests entirely on future clinical success. The most pessimistic target, $114.00, is roughly what SYRE is worth if this bites instead.
Read the full bull and bear case on SYRE, including what would have to change to break either one. Walnut is not an investment adviser.
Has Spyre Therapeutics, Inc. (SYRE) split its stock?
Yes. Spyre Therapeutics, Inc. (SYRE) has had one share split in the last 10 years:
- 1:25 on September 8, 2023, so every share held became 0.04 shares.
A split changes the share count and the price per share and leaves the value of a holding unchanged. Someone holding $1,000 of SYRE the day before the 1:25 split held $1,000 the day after, in more shares at a proportionally lower price. Historical prices from before the date are normally shown split-adjusted, which is why a long-run chart shows no cliff.
Splits matter mainly because they make older price figures confusing to compare by hand, and because a board choosing to split is usually signalling that the price has run up far enough to feel awkward for smaller buyers. Neither is a reason to buy or sell.
How is Spyre Therapeutics, Inc. (SYRE) valued?
Market cap, P/E and dividend yield at today's price are in the SYRE key stats above. The business figures below come from Spyre Therapeutics, Inc.'s reported results as of November 2026 and change when it next reports.
- Product revenue (TTM): ~$0 (clinical-stage)
- Net loss (last four quarters): ~-$264M
- Q3 2026 net loss: ~-$96M (EPS -$0.94 vs ~-$0.84 est.)
- Cash (Sept 30, 2026): ~$1.07B, no debt; ~$1.47B pro forma
- 52-week range: ~$23.01 to ~$110.64
As of November 2026: Spyre has no product revenue and posts steady losses funding R&D, so traditional earnings and valuation multiples do not apply. Its roughly $8.9 billion market cap (November 20, 2026) reflects expectations for its TL1A, IBD and newer dermatology pipeline, not current cash flow, and sits about 9x book value. Investors weigh a pro forma cash position near $1.47 billion and runway into the second half of 2029 against clinical milestones, the next large one being SKYLINE combination data in Q3 2027.
Who competes with Spyre Therapeutics, Inc. (SYRE)?
Large-cap TL1A developers
Merck (tulisokibart, from its Prometheus acquisition), Roche (RVT-3101/afimkibart, via Telavant), and Sanofi/Teva (duvakitug) are pursuing the same TL1A target for IBD with far greater resources and, in Merck's case, registrational Phase 3 data already in hand. They are Spyre's most direct threat to be first to market.
Established IBD biologics makers
AbbVie (Skyrizi, Rinvoq), Takeda (Entyvio/vedolizumab), and Johnson & Johnson (Tremfya) already sell approved IBD therapies. Any new entrant like Spyre must show meaningful advantages in efficacy, safety, or dosing convenience to displace incumbents with entrenched physician relationships.
Other emerging antibody biotechs
Companies such as Absci (ABS-101, an AI-designed TL1A antibody) and other clinical-stage immunology players are advancing next-generation candidates. They compete with Spyre for trial patients, scientific talent, partnering interest, and investor capital in a crowded inflammation field.
What stocks are similar to Spyre Therapeutics, Inc. (SYRE)?
Other names that sit close to SYRE: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in Spyre Therapeutics, Inc. (SYRE)
There are three common ways to get SYRE exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so SYRE sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where SYRE fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Spyre Therapeutics, Inc. (SYRE)
Spyre is a binary, catalyst-driven clinical-stage biotech whose story hinges on 2027 trial data, not current financial results. After the October 2026 stock sale and at-the-market sales, pro forma cash was about $1.47 billion, which the company says funds operations into the second half of 2029, so funding is not the near-term question; the data are. The 2026 results split: all three IBD monotherapies completed proof-of-concept in SKYLINE, while SPY072 missed in two rheumatic sub-studies and will not be advanced there. IBD combination data are expected in Q3 2027.
More on Spyre Therapeutics, Inc. (SYRE)
Whether SYRE is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is SYRE a buy or a sell?, and where the stock could go from here in the SYRE stock forecast.
For income investors, whether SYRE pays a dividend and how the payout looks is covered in does SYRE pay a dividend? And to weigh SYRE against a peer, read the full side-by-side comparisons: SYRE vs SNY and SYRE vs ABBV.
Wondering how SYRE fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Spyre Therapeutics, Inc.
Ask Walnut's AI anything about SYRE and see how it fits what you own.
FAQ
What does Spyre Therapeutics do?
+
Spyre is a clinical-stage biotech developing long-acting antibodies and antibody combinations for inflammatory bowel disease (ulcerative colitis and Crohn's) and hidradenitis suppurativa. It also tested SPY072 in rheumatic diseases but, after misses in two sub-studies, does not plan to advance it there. Its lead programs target the TL1A pathway and are engineered for less frequent dosing than existing biologics.
Is SYRE profitable?
+
No. Spyre has no marketed products and generates no product revenue, posting net losses of about $264 million over the last four reported quarters (Q3 2026 alone was about $96 million, against $11 million a year earlier). Like most clinical-stage biotechs, it spends heavily on research while pursuing trials, and analysts expect a wider loss in 2027.
How much cash does Spyre have?
+
Spyre held about $1.07 billion in cash, cash equivalents and marketable securities with no debt at September 30, 2026. In October 2026 it priced an upsized public offering of about 4.1 million shares at $85, bringing in $378 million of net proceeds, and sold another $18 million through its at-the-market program, for pro forma cash of about $1.47 billion. The company expects that to fund operations into the second half of 2029.
What are Spyre's key catalysts?
+
The 2026 Phase 2 proof-of-concept readouts are largely complete: SKYLINE Part A in ulcerative colitis was positive for all three monotherapies, while SKYWAY in rheumatic diseases was positive only in rheumatoid arthritis. Next come SKYLINE Part B induction data for three combinations in Q3 2027, the start of a registrational TL1A study in HS in 2027, and SKYLIGHT HS results in late 2027 or early 2028. Each readout is a potential value-moving event in either direction.
Who competes with Spyre in the TL1A space?
+
Larger developers include Merck (tulisokibart), Roche (afimkibart/RVT-3101), and Sanofi/Teva (duvakitug), several of which are ahead in development. Spyre also competes broadly with established IBD biologics from AbbVie, Takeda, and Johnson & Johnson.
Why has SYRE stock been volatile?
+
As a pre-revenue biotech, Spyre's price swings on clinical data and financing news, not earnings, and its beta near 3 reflects that. Its 52-week range ran from about $23.01 to $110.64, and the shares fell about 14% on the day its $350 million offering was priced in October 2026, showing how sharply sentiment can shift.
Does Spyre pay a dividend?
+
No. Spyre is an unprofitable clinical-stage company that reinvests all capital into research and development, so it pays no dividend. Any cash it raises goes toward funding trials rather than returning money to shareholders.
What is the main risk with SYRE?
+
The central risk is clinical failure: with no product revenue, the valuation depends entirely on trial success, and the SKYWAY misses in psoriatic arthritis and axial spondyloarthritis show that not every readout goes the company's way. The Q3 2027 combination data in IBD is the next large test. Intense TL1A competition and future dilution add further risk.
How has SYRE stock performed in 2026?
+
As of November 20, 2026, SYRE closed at about $94.07, up roughly 208% year to date and about 301% over the past year, for a market cap near $8.9 billion. It is down about 12% over three months from a 52-week high of about $111, after a drop on the October stock offering. The average analyst target is about $124, with a strong-buy consensus across 15 analysts, and Deutsche Bank raised its target to $141 from $123 on November 13.
Why did Spyre sell stock in October 2026?
+
On October 5, 2026 Spyre priced 4,117,648 shares at $85.00 for about $350 million of gross proceeds, or $378 million net including the underwriters' option, according to its Q3 report. The company said the money will advance its gastroenterology, rheumatology and dermatology programs, including Phase 3 readiness and a new late-stage program in hidradenitis suppurativa, plus general research and corporate purposes.
How did Spyre do in its latest quarter?
+
For Q3 2026, reported November 3, Spyre posted a net loss of $96.1 million, or $0.94 per share, against a ~$0.84 consensus loss, as R&D expenses rose to $89.2 million from $45.2 million a year earlier on manufacturing and trial costs. It reported $1.07 billion of cash and securities at quarter end, $1.47 billion pro forma, and runway into the second half of 2029.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Spyre Therapeutics, Inc.'s investor relations page or your broker before making investment decisions.